Intellia Therapeutics Inc (NTLA) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Intellia Therapeutics Inc   (NASDAQ: NTLA)

Intellia Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Intellia Therapeutics Inc in the second quarter 2026?
Intellia Therapeutics Inc recorded a cumulative net loss of $-400 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -57.79%.

Within the In Vitro & In Vivo Diagnostic Substances industry 6 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 3609, from total ROE ranking in the first quarter 2026 at 4184.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change - -20.38 % -23 % -22.25 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -400 -395 -413 -446 -480
Return On Equity (TTM) -57.79 % -119.08 % -111.2 % -105.83 % -101.13 %
NTLA's Total Ranking # 3609 # 4184 # 3621 # 3651 # 3447
Equity (TTM) in Millions 728 621 671 748 -715
Seq. Equity Change 17.19 % -7.51 % -10.29 % - -
Seq. Net Income Change - - - - -

Back to NTLA Management Effectiveness >> NTLA's 5 Years Annual ROE >> Compare NTLA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 7
Sector # 438
Overall # 3609

Return On Equity Statistics
High Average Low
-17.65 %
-45.64 %
-119.08 %
(Mar 31 2017)   (Mar 31 2026)





NTLA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 671 872 1,050 1,236 1,040
Y / Y Equity Change -23 % -16.97 % -15.01 % 18.78 % 97.36 %
Net Income in Millions -413 -519 -481 -474 -268
Y / Y Net Income Change - - - - -
Return On Equity -61.47 % -59.52 % -45.82 % -38.38 % -25.75 %

Back to NTLA Management Effectiveness >> NTLA's 5 Years Annual ROE >> Compare NTLA ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NTLA's' Return on Equity at Yahoo Finance
NTLA's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NTLA's Competitors
Subscribers only: Roe for Intellia Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for NTLA's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-26T07:28:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.